Montana M, Ducros C, Verhaeghe P, Terme T, Vanelle P, Rathelot P
Laboratoire de Pharmaco-Chimie Radicalaire, Faculté de Pharmacie, Universités d’Aix-Marseille I, II et III, CNRS-UMR 6264 Laboratoire de Chimie Provence 27, boulevard Jean Moulin, 13385 Marseille 5, France.
J Chemother. 2011 Apr;23(2):59-66. doi: 10.1179/joc.2011.23.2.59.
Paclitaxel and docetaxel are established as the standards of care, either as monotherapy or in combination with other cytotoxic agents in metastasic breast cancer. In order to improve the efficiency of solvent-based paclitaxel and to overcome its drawbacks in terms of safety, a solvent-free formulation has been developed. This work is a review of the albumin-bound paclitaxel data relative to its pharmacodynamic and pharmacokinetic profiles, its therapeutic efficiency and its safety of use. The activity of albumin-bound paclitaxel in phase II and III trials indicates its significant clinical efficiency in the treatment of metastatic breast cancer. In lung and pancreatic cancer and in melanoma, the use of albumin-bound paclitaxel leads to interesting results which require further investigations. Preclinical and clinical studies have shown that albumin-bound paclitaxel is associated with a better tolerance compared to standard paclitaxel.
紫杉醇和多西他赛已成为转移性乳腺癌治疗的标准方案，可作为单一疗法或与其他细胞毒性药物联合使用。为了提高基于溶剂的紫杉醇的效率并克服其在安全性方面的缺点，已开发出一种无溶剂制剂。这项工作是对白蛋白结合型紫杉醇的数据进行综述，内容涉及其药效学和药代动力学特征、治疗效果及使用安全性。白蛋白结合型紫杉醇在II期和III期试验中的活性表明其在转移性乳腺癌治疗中具有显著的临床疗效。在肺癌、胰腺癌和黑色素瘤中，使用白蛋白结合型紫杉醇取得了令人感兴趣的结果，有待进一步研究。临床前和临床研究表明，与标准紫杉醇相比，白蛋白结合型紫杉醇具有更好的耐受性。
